synovitis by local injection of cytokines,2 and the ability to block the pathology of experimental models of arthritis by anticytokine reagents3 4 strongly argue that these potent local hormones play a key role in the pathology of chronic arthritic conditions such as rheumatoid arthritis (RA) and septic arthritis. It is not surprising, therefore, that the cytokines are perceived as major therapeutic targets in these conditions. The first faltering attempts to develop anticytokine agents started only a short time ago, in the mid 1980s, but through the growth in the biopharmaceutical industry in the past decade we currently have a number of anticytokine agents in clinical trials. This paper will consider briefly the methods used to modulate cytokines, and interested readers should refer to recent reviews for more details. 5 6 Therapeutic modulation of cytokines Four major approaches to therapy can be taken: inhibit cytokine synthesis; inhibit cytokine release; inhibit cytokine action; inhibit cytokine intracellular signalling pathways. Table 1 shows the various points of intervention, which will be considered in turn.
INHIBITION OF CYTOKINE SYNTHESIS
This can be achieved at a number oflevels. The first is blockade of the intracellular signalling pathways which result in the transcription of individual cytokine genes. In the past few years it has been demonstrated that the potent immunosuppressants cyclosporine and FK506 inhibit the synthesis of lymphokines such as IL-2, IL-3, IL-4, and interferon gamma in this manner by forming a complex with specific cellular binding proteins which then inhibits the calmodulin-dependent protein phosphatase, 25 These discrepant results may reflect the different response of these experimental lesions to nonsteroidal anti-inflammatory drugs (NSAIDs). Adjuvant and collagen arthritis are largely cured by NSAIDs, while this class of drug has no effect on the progressive damage to articular cartilage and bone damage in antigen induced arthritis models-a reflection of the clinical experience with these drugs. As TNFa is a potent inducer of cyclo-oxygenase II and thus stimulates prostanoid synthesis, the neutralisation of this cytokine would be likely to inhibit prostanoid formation, and this could be responsible for some of the reported effects. We have found that a neutralising MAb to rabbit TNFa has a profound antiinflammatory effect in animals with antigen induced arthritis, complete inhibition of joint swelling occurring within with one week of treatment-an effect we have seen with no other drug tested. However, these animals showed no inhibition of cartilage proteoglycan loss.25 This substantiates the growing belief that tissue damage and inflammation in the rheumatoid joint may not be causally linked. 26 Two additional problems are faced by antibodies. First, if articular cartilage chondrocytes are producing the cytokines which, acting in an autocrine fashion, stimulate the degradation of cartilage, then neutralising antibodies may not be able to penetrate the cartilage to switch off synthesis. This may be one explanation for our failure to inhibit cartilage damage in the rabbit. Second, with fully humanised antibodies the prolonged administration of large amounts of a particular idiotope is likely to induce an antiidiotypic response. Of particular concern is the possibility that some of these anti-idiotypic antibodies could mimic TNFa and thus exacerbate the disease.
One exciting development which could overcome these various problems is the work of Saragovi's group, who have reported the synthesis of low molecular weight non-peptide mimetics of antibody combining sites. 27 Cytokine antagonists-When pharmacologists think about inhibiting the action of an agonist, their first thought is to develop a receptor antagonist. Such ideas initiated the drive to develop anticytokine therapeutic agents, but in spite of extensive and expensive research no pharmaceutical company has yet devised a cytokine receptor antagonist. The reasons for this probably relate to the enormously high affinities of binding between cytokines and their receptors and the multipoint attachment of these two cognate proteins. However, Mother Nature has had many aeons of pharmaceutical experimentation and has developed an antagonist of IL-1. This protein, interleukin-1 receptor antagonist (IL-Ira), shares only 20-30% homology with the IL-is, but is now regarded as the third member of the IL-1 family and binds to the fumctional type I IL-1 receptor without stimulating an agonist response. It is therefore a useful probe of the residues in IL-lra which trigger receptor mediated cellular activation.30 First described in the late 1980s, and cloned and expressed in 1990,3 during the past four years IL-Ira has been shown to be a potent inhibitor of many experimental models of human disease and, in particular, septic shock6 and has been tested in clinical trials for various conditions. It has been shown to ameliorate rodent models of arthritis,32 but had no effect on the induction33 or (Lewthwaite, in preparation) chronic phase of antigen induced arthritis in the rabbit. However, it has proved to be a potent antifibrotic agent in both lung34 and joints (Lewthwaite, 
